Targeting Malt1 With The Small Molecule Inhibitor Mi2 Induces A Caspase-Dependent Apoptosis And Inhibits The Nf-Kappa B Pathway In Chronic Lymphocytic Leukemia Primary Cells

Targeting the B-cell receptor (BCR) pathway in chronic lymphocytic leukemia (CLL) with the Bruton Tyrosine Kinase (BTK) inhibitor Ibrutinib has transformed the treatment paradigm of this disease. Ibrutinib is currently indicated for treatment of CLL regardless of the line of therapy. However, ibrutinib is not curative, and relapses secondary to C481S mutation in BTK and gain of function mutations in PLCγ2 (R665W and L845F) are being reported.